Johnson & Johnson : JNJ

All Johnson & Johnson Articles

1094 Articles

Lee Jackson | Aug 24, 2015 at 8:10 AM EDT

4 Defensive Stocks to Buy for Continued Market Volatility

In a new research report, the technical team at RBC highlight stocks and sectors that are working and are clearly…

Douglas A. McIntyre | Aug 24, 2015 at 6:29 AM EDT

Where Will Warren Buffett Put Money as Markets Collapse?

Where will the most brilliant investor in the world put his money if the markets collapse? Perhaps into some of…

Jon C. Ogg | Aug 10, 2015 at 3:19 PM EDT

Why AbbVie Should Be Worth 25% More

Independent research firm Argus has maintained its Buy rating and its $85.00 price target on AbbVie.

Douglas A. McIntyre | Aug 2, 2015 at 8:00 AM EDT

5 Dividend Stocks for Your Portfolio

Stockcharts.comLong-term investors always look for companies that show signs that they will be around for a while. Membership on the…

Paul Ausick | Jul 17, 2015 at 4:01 PM EDT

The 4 Stocks That Sank the DJIA on Friday

July 17, 2thinkstock015: Markets opened mixed on Friday as the Nasdaq traded higher right from the opening bell and the…

Lee Jackson | Jul 16, 2015 at 9:35 AM EDT

UBS Makes Summer Changes to Dividend Ruler Stocks Portfolio

A new report from UBS includes changes to the firm's Dividend Ruler stocks portfolio. Also featured are the current four…

Chris Lange | Jul 14, 2015 at 8:40 AM EDT

Johnson & Johnson Posts Q2 Earnings Beat

Johnson & Johnson reported better-than-expected second-quarter financial results before the markets opened Tuesday.

Chris Lange | Jul 13, 2015 at 11:10 AM EDT

What to Expect From Johnson & Johnson Earnings

Johnson & Johnson is expected to report its second-quarter financial results Tuesday morning before the markets open.

Chris Lange | Jul 12, 2015 at 9:10 AM EDT

6 Key DJIA Earnings for the Week Ahead

Earnings season for the second quarter of the calendar year has kicked off, and 24/7 Wall St. has put together…

Lee Jackson | Jul 7, 2015 at 10:20 AM EDT

UBS Makes Changes to Dividend Ruler Stock List

With the Greek debacle throwing some very cold water on the market, it makes sense for investors to use cash…

Chris Lange | Jul 7, 2015 at 7:35 AM EDT

5 Big Upcoming FDA Decisions Expected in July

24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of July and…

Paul Ausick | Jun 18, 2015 at 4:01 PM EDT

The 4 Stocks That Dominated the DJIA on Thursday

thinkstockJune 18, 2015: Markets opened higher on Thursday based on the FOMC’s decision to leave interest rates alone and generally…

Douglas A. McIntyre | Jun 13, 2015 at 9:25 AM EDT

Great Stocks for the Elderly

Older Americans, in many cases, have lost their tolerance for financial risk and they want to protect the size of…

Chris Lange | Jun 8, 2015 at 1:00 PM EDT

Autoimmune Drugs to Drive Big Pharma Higher in Coming Years

Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical…

Lee Jackson | Jun 6, 2015 at 9:15 AM EDT

Insider Buying Still Strong as Market Volatility Spikes

The jump in market volatility did not deter executives and 10% shareholders this week, and insider buying stayed solid.

1 … 35 36 37 38 39 … 73

Johnson & Johnson : JNJ

All Johnson & Johnson Articles

4 Defensive Stocks to Buy for Continued Market Volatility

Where Will Warren Buffett Put Money as Markets Collapse?

Why AbbVie Should Be Worth 25% More

5 Dividend Stocks for Your Portfolio

The 4 Stocks That Sank the DJIA on Friday

UBS Makes Summer Changes to Dividend Ruler Stocks Portfolio

Johnson & Johnson Posts Q2 Earnings Beat

What to Expect From Johnson & Johnson Earnings

6 Key DJIA Earnings for the Week Ahead

UBS Makes Changes to Dividend Ruler Stock List

5 Big Upcoming FDA Decisions Expected in July

The 4 Stocks That Dominated the DJIA on Thursday

Great Stocks for the Elderly

Autoimmune Drugs to Drive Big Pharma Higher in Coming Years

Insider Buying Still Strong as Market Volatility Spikes

Jill Schlesinger Greenlights $2.9M Retiree’s $200K Gift to Sons: ‘I Can’t Believe I’m Being the Dream Maker’

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

Rivian Tops Q1 Estimates, but Investors Investors Rightly Remain Wary

Jill Schlesinger Greenlights $2.9M Retiree's $200K Gift to Sons: 'I Can't Believe I'm Being the Dream Maker'

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

Jill Schlesinger Greenlights $2.9M Retiree’s $200K Gift to Sons: ‘I Can’t Believe I’m Being the Dream Maker’

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

Johnson & Johnson : JNJ

All Johnson & Johnson Articles

4 Defensive Stocks to Buy for Continued Market Volatility

Where Will Warren Buffett Put Money as Markets Collapse?

Why AbbVie Should Be Worth 25% More

5 Dividend Stocks for Your Portfolio

The 4 Stocks That Sank the DJIA on Friday

UBS Makes Summer Changes to Dividend Ruler Stocks Portfolio

Johnson & Johnson Posts Q2 Earnings Beat

What to Expect From Johnson & Johnson Earnings

6 Key DJIA Earnings for the Week Ahead

UBS Makes Changes to Dividend Ruler Stock List

5 Big Upcoming FDA Decisions Expected in July

The 4 Stocks That Dominated the DJIA on Thursday

Great Stocks for the Elderly

Autoimmune Drugs to Drive Big Pharma Higher in Coming Years

Insider Buying Still Strong as Market Volatility Spikes

Jill Schlesinger Greenlights $2.9M Retiree’s $200K Gift to Sons: ‘I Can’t Believe I’m Being the Dream Maker’

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

Rivian Tops Q1 Estimates, but Investors Investors Rightly Remain Wary

Featured Reads

Jill Schlesinger Greenlights $2.9M Retiree's $200K Gift to Sons: 'I Can't Believe I'm Being the Dream Maker'

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts